Drug intelligence / Profile preview

RK006

Development stage: Preclinical
Lead developer: RevolKa
Modality: Recombinant Proteins and Enzymes

Overview

RK006 is a protein-based therapeutic candidate currently in development by RevolKa. It was generated using RevolKa's proprietary protein engineering platform, which utilizes directed evolution and artificial intelligence to optimize protein functions. As of the current pipeline disclosures, the specific molecular target and primary disease indication for RK006 remain undisclosed by the company. The program has completed an undisclosed early development stage within RevolKa's internal research framework.

Beyond the preview

Go deeper on RK006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RK006.

Explore the full profile